Medicinal Cannabis Funding in the UK

Prepared and last reviewed: 12 November 2026.
Written by the Weed Supermarket Editorial Team.

Where the Money Goes

Medicinal cannabis funding is back in the UK headlines after Grow Group announced a £12 million financial restructuring. But the headline figure needs unpacking. Some funding pays for new facilities or research. Other deals give a company more time to repay existing debt. For anyone following this industry, the useful question is where the money goes. Does it support reliable medicine supply, better clinical evidence or a stronger balance sheet? And does any of it change what patients can access?

This guide explains the main routes into UK medicinal cannabis finance, the recent announcements worth understanding and the limits of what an investment headline can tell us.

Medicinal cannabis funding at a glance

Funding route	What it does	What to check
Equity investment	Investors provide money in return for ownership.	How much fresh cash arrives and how ownership changes.
Loans and refinancing	A business borrows money or changes existing repayment terms.	Interest, security, repayment dates and conditions.
Research grants	Money supports a defined scientific project.	The award recipient, study aims and spending restrictions.
Commercial partnerships	Businesses share resources, development costs or distribution opportunities.	Whether any payment is guaranteed or depends on milestones.
NHS treatment funding	Public money pays for care under relevant NHS arrangements.	Clinical eligibility, evidence and commissioning decisions.

These routes can overlap, but they are not interchangeable. A research award does not automatically pay a patient’s prescription bill. Equally, a company can raise money without proving that its medicine works.

Grow Group: what the £12 million deal actually means

Sky News reported the Grow Group funding story on 10 November 2026. The following day, a published company statement set out the structure of the transaction, completed on 3 November.

The package comprised £2 million of new cash equity, mainly from existing shareholders, and £10 million of debt converted into shares or extended to later repayment dates. The announcement did not give a separate amount for each of those two debt measures.

It would therefore be inaccurate to describe the whole £12 million as fresh cash investment. The cash supports working capital, while the debt changes alter existing obligations.

Grow also announced Clare Holliday and Pierre van Weperen as co-chief executives. It said its UK manufacturing facility was fully operational and set out an expectation of positive EBITDA in 2027. That is a management forecast, not an achieved result. EBITDA is an earnings measure before interest, tax, depreciation and amortisation; it is not the same as cash flow or net profit.

Where medicinal cannabis funding goes

A cannabis business can need money long before it receives payment for a finished medicine. Its spending also depends on its role. A grower, importer, pharmacy and drug developer have very different cost structures.

Facilities, manufacturing and quality systems

Controlled production requires premises, equipment, trained staff and documented processes. Businesses must budget for the licences and standards relevant to their activities. Those costs can arise before commercial output begins.

A new building alone does not establish a viable business. It also needs customers, suitable products and enough money to cover the period between production and payment.

Stock and day-to-day cash

Working capital pays for ordinary operations. Examples include inventory, wages, testing and supplier invoices. Even a business with growing sales can run short of cash if it pays suppliers well before customers pay it.

This is why a smaller cash injection can matter more immediately than a much larger headline valuation. Valuation describes an agreed or estimated business value. It does not tell us how much money is available in the bank.

Clinical development

Research spending can cover study design, trial medicines, recruitment, monitoring and data analysis. However, a promising early result may still need further testing. Each stage takes time and can produce disappointing findings.

Investors and readers should ask what a study will establish. Evidence about one formulation, dose and patient group cannot simply be transferred to every cannabis-derived product.

Public research funding: two UK developments in 2026

More than £9 million for epilepsy trials

In a parliamentary answer dated 21 April 2026, the Department of Health and Social Care confirmed that NIHR and NHS England had committed over £9 million to clinical trials. These will investigate CBD and a CBD/THC combination for drug-resistant epilepsies in adults and children.

The stated purpose is to produce evidence that can inform future clinical and commissioning decisions. This is research funding, not a general promise of NHS prescriptions or proof that the treatments will succeed.

Ananda’s trial milestone

A July 2026 announcement from Ananda Pharma reported the first patient dosed in the ACTiON trial. The study is investigating its CBD-based MRX1 candidate for chemotherapy-induced peripheral neuropathy.

The company described the trial as funded through an NIHR Efficacy and Mechanism Evaluation grant and led by the University of Edinburgh. The planned study compares treatment with placebo. Starting a trial is a development milestone, not evidence of a proven benefit.

Together, these examples show why medicinal cannabis funding involves more than growers and private investors. Universities, public research bodies and commercial developers can play distinct roles.

Equity, debt and grants: who carries the risk?

Equity means sharing ownership

New investors may buy shares directly from a company. Existing owners can then hold a smaller percentage of the business, known as dilution. In return, the company receives capital without the repayment schedule of an ordinary loan.

However, buying an existing shareholder’s shares is different. That payment usually goes to the seller, rather than into the business. A share purchase and a company fundraise are not automatically the same thing.

Debt creates repayment obligations

A loan can support growth without immediately changing ownership. But interest and repayment obligations can put pressure on cash flow. Some loans also give lenders security over assets.

Refinancing replaces or changes those obligations. Extending a repayment date may provide breathing room, but it does not necessarily reduce the principal owed. Converting debt into equity changes the lender’s position into an ownership stake.

Grants have a defined purpose

A research grant can support work without issuing shares. Nevertheless, it comes with conditions. It may be awarded to a university or research partnership rather than paid freely into a company’s general account.

Check the named recipient and project scope before treating a grant headline as corporate income. An award can be scientifically valuable without funding the rest of a business.

London’s capital markets and cannabis investment

London is an obvious visual backdrop for this subject, but a City connection does not mean every medicinal cannabis company is stock-market listed. Businesses can raise money privately, and trading status can change.

There is also a legal distinction between different cannabis activities. ICAEW’s guidance on cannabinoid investments highlights anti-money-laundering and proceeds-of-crime considerations. An activity being permitted overseas does not, by itself, settle its treatment under UK law.

For that reason, cannabis investment needs more than a market forecast and a familiar company name. The activities, jurisdictions, licences and source of revenues all matter. Specialist legal and financial advice may be necessary.

A stock exchange admission is not a medical endorsement. Nor does it guarantee a return, protect investors from losses or establish that every product has a marketing authorisation.

Does more investment mean better patient access?

Potentially, investment can help a business build capacity, improve supply systems or support research. But the link is not automatic. Funding may also be needed simply to maintain operations or manage existing debt.

NHS access involves separate clinical and funding decisions. The NHS medical cannabis information page explains that very few people in England are likely to receive an NHS prescription. Private company investment does not change that position by itself.

Readers looking for practical patient information can use our guide to NHS and private medical cannabis prescription routes. Our UK medicinal cannabis and ACMD review article covers the separate policy debate.

For consumers, reliable supply and clearer evidence matter more than the size of a fundraising headline. Lower prices, wider eligibility and better outcomes should each be demonstrated, rather than assumed.

How to read a medicinal cannabis funding announcement

1. Check the date. A recently shared article may describe an older transaction.
2. Separate fresh cash from existing debt, share swaps and headline valuations.
3. Check whether funding is completed, proposed or dependent on conditions.
4. Identify who receives the money and what it can be used for.
5. Distinguish current results from management forecasts.
6. Check whether claimed sales are revenue, orders or expressions of interest.
7. Look for evidence behind medical statements and confirm the relevant licences.
8. Ask what happens if the next fundraise, trial or commercial milestone is delayed.

These questions make medicinal cannabis funding news more useful without turning an industry article into an investment tip sheet.

Medicinal cannabis and retail cannabinoids are different markets

Prescription medicines and retail cannabinoid products should not be presented as equivalent. Their intended uses and regulatory routes differ. A business supplying medicines also needs the permissions appropriate to its specific activities.

The Home Office cannabinoid licensing factsheet explains important distinctions between controlled cannabis products, medicines and isolated CBD. A cannabinoid’s name alone does not establish the legal status of a finished product.

Our UK Compliance and Laboratory Testing Statement explains our approach to product information. Weed Supermarket does not prescribe medicines, and this article does not suggest that retail products can replace prescribed treatment.

Frequently asked questions

What is medicinal cannabis funding?

It can mean investment in cannabis medicine businesses, finance for clinical research or funding for patient treatment. The context matters because each route has different recipients, conditions and aims.

Did Grow Group raise £12 million in new cash?

No. Its announced package included £2 million of new cash equity and £10 million of existing debt converted or extended. The full package should not be described as fresh cash.

Does the UK fund medicinal cannabis research?

Yes. Public funding supports specific research projects, including the epilepsy trials discussed above. Awards are tied to research aims and do not establish that a treatment is effective.

Does company investment pay for NHS prescriptions?

Not automatically. Corporate finance and NHS treatment funding are separate. A successful fundraise does not create a right to an NHS prescription or remove clinical requirements.

Can medicinal cannabis businesses raise money privately?

Yes. A stock-market listing is not the only route. Depending on the business and applicable rules, funding may come from shareholders, lenders, commercial partners or other private investors.

Are cannabis investments guaranteed to grow?

No. Investors can lose money. Regulatory changes, weak cash flow, competition, research setbacks and further fundraising needs can all affect a business. Sector growth does not guarantee success for an individual company.

Will more funding make medicinal cannabis cheaper?

It might improve efficiency or supply, but cheaper treatment is not guaranteed. Production costs, clinical services, distribution and commercial decisions all affect the price paid by patients.

Editorial compliance statement

This article provides general industry information based on sources reviewed on 12 November 2026. It is not investment, financial, legal or medical advice, an invitation to invest, or a recommendation of any company, security or treatment. Company announcements contain management statements that may change. Financial forecasts and research milestones do not guarantee commercial success or clinical benefit.

Weed Supermarket does not diagnose, prescribe or replace advice from a qualified healthcare professional. References to companies, research institutions and London financial markets do not imply affiliation or endorsement. Consult appropriately qualified advisers for decisions about investment, legal compliance or individual treatment.